title: [Role of islacet (an extract from Island cethraria thalluses) in the complex therapy of experimental tuberculosis].
abstract: In vitro experiments showed that islacet produced an inhibitory effect on the growth of laboratory drug-sensitive Mycobacterium strains when used at a concentration of 25 microg/ml. A considerable reduction in death rates and a significant decrease in the mass index and in the indices of pulmonary lesion and bacterial isolation from splenic homogenates were observed on the model of generalized tuberculosis in mice and rabbits given islacet. In parallel with the higher efficiency of therapy using islacet, there was ConA- and PPD- stimulated proliferation of splenocytes and their production of interleukin-2 drastically inhibited in mice that had long received multidrug therapy (HRZ and HRE). Islacet was found to enhance the functional activity of phagocytes and that inhibited during the development of infection and under the influence of long-term (more than 1 month) etiotropic therapy: the generation of superoxide by murine peritoneal macrophages and rabbit neutrophils, as well as by the absorptive and digestive function of peritoneal macrophages.
authors.forename: M L
authors.initials: ML
authors.lastname: Vitovskaia
authors.forename: T i
authors.initials: Ti
authors.lastname: Vinogradova
authors.forename: N V
authors.initials: NV
authors.lastname: Zabolotnykh
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Safonova
mesh_terms: D000818:Animals; D000995:Antitubercular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001203:Ascomycota / Q000737:chemistry*; D001688:Biological Products / Q000494:pharmacology / Q000627:therapeutic use*; D051379:Mice; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D011817:Rabbits; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000995:Antitubercular Agents; D001688:Biological Products